Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pernix Theraptcs Cmn (PTX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 26,500
  • Shares Outstanding, K 8,510
  • Annual Sales, $ 175,850 K
  • Annual Income, $ -148,320 K
  • 36-Month Beta 1.75
  • Price/Sales 0.17
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +57.92%
on 12/28/16
3.95 -26.84%
on 01/17/17
+0.10 (+3.58%)
since 12/19/16
3-Month
1.83 +57.92%
on 12/28/16
4.68 -38.25%
on 10/25/16
-0.43 (-12.95%)
since 10/19/16
52-Week
1.83 +57.92%
on 12/28/16
24.70 -88.30%
on 01/28/16
-17.21 (-85.62%)
since 01/19/16

Most Recent Stories

More News
Pernix Therapeutics Appoints Ken Pina as General Counsel and Chief Compliance Officer

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on pain and CNS conditions, today announced the appointment of Ken Pina as Senior Vice President, General...

Drug Makers Stocks Under Scanner -- Novo Nordisk, Synergy Pharma, Pernix Therapeutics, and Apricus Biosciences

Stock-Callers.com revisits the Drug Manufacturers industry, which is focused on the research, distribution, and marketing of pharmaceutical drug products. Companies in this space can greatly be affected...

Pernix Therapeutics Appoints New Board Member

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the appointment of Gabriel Leung to its Board of Directors,...

Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

Net Revenue Increased 13% Sequentially Over Second Quarter 2016

Pernix Therapeutics Appoints Two Board Members

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the appointment of Graham G. Miao, Ph.D. and Dennis H. Langer,...

Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, and Apricus Biosciences

On Monday, October 31, 2016, the NASDAQ Composite ended the trading session at 5,189.13, down 0.02%; the Dow Jones Industrial Average edged 0.10% lower, to finish at 18,142.42; and the S&P 500 closed at...

Pernix Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that the Company will report financial results for the third...

Pernix Therapeutics Announces Reverse Stock Split and Corporate Governance Enhancements

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that its Board of Directors unanimously approved a reverse split...

Pernix Therapeutics Announces Distribution of TREXIMET(R) 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced the distribution of TREXIMET(R) (sumatriptan and naproxen sodium)...

Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing(R)

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that Marsha Stanton, Ph.D., RN, Executive Director of Medical...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company's product families include Aldex, Pediatex, Z-Cof, Brovex,...

See More

Support & Resistance

2nd Resistance Point 3.37
1st Resistance Point 3.21
Last Price 2.83
1st Support Level 2.94
2nd Support Level 2.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.